SYSTEMIC THERAPY ELIGIBILITY CRITERIA OF THE INTERNATIONAL PSORIASIS COUNCIL MAY REDUCE UNDERTREATMENT OF PSORIASIS PATIENTS WITH LOW BODY SURFACE AREA INVOLVEMENT ASSOCIATED WITH HIGH DISEASE BURDEN

Alexander Litvintchouk¹, Jing Zhao¹, Oluwakayode Adejoro¹ 1. Janssen Global Services, LLC, a Johnson & Johnson Company

R	ACKGROUN					RESULTS				
D				•						<u>.</u>
•	•		•	t for PsO, meas		 3,866 PsO pat 				
				., body surface	 Disagreement based on severity was significant (1) 					
	and Psoriasis		Table 2: Patient Demographics and Current Disease Activi							
	reimbursement and therapeutic decisions, as systemic therapies are traditionally reserved for patients with					Disagreement Between Clinician Assessments and IPC Cri				
							Agreement and D			
	moderate-sev	ere disease		Agreement bet						
•	In 2020, the Ir	nternationa	Characteristic	Mild N = 442		erate/Severe N= 1684				
	three criteria	(i.e., BSA ≥	10%, sensiti	ve body area ir	Age (years)	IN - 442		IN- 1004		
	failure of topic	cal therapy	control) tha	, at should be co	n	200	749		824	
		• •	-	therefore pati	'' Mean (SD)	45.8 (15.3)	42.9 (1-	4.47)	45.9	
	evaluating elig	_	_	-	Median (Q1,Q3)	43.5 (34.5, 57.0)	· ·	2.0, 52.0)	45.0	
	evaluating eng	gionity for s	systemic the	гару.		Min, Max	16.0, 90.0	13.0 <i>,</i> 8	· ·	17.0
						Race, n (%)				
		OBJ	ECTIVES			Caucasian	387 (87.6%)	1472 (8	37.4%)	149
•	To understand	d level of ag	greement be	etween physicia	ans and the	Other Races	55 (12.4%)	212 (12	2.6%)	212
	IPC criteria foi	r eligibility	for systemic	therapy		Sex, n (%)				
•				for eligibility fo	r systemic	Female	202 (45.7%)	756 (44	•	738
				low BSA assoc			239 (54.1%)	927 (55	5.0%)	960
	• •	2 1			Provider & Patient (•		7 00/)	220	
	significant dis	ease purce	en or worse (Jucomes		France	78 (17.6%) 19 (4.3%)	286 (17 342 (20		230 237
						Germany Italy	96 (21.7%)	189 (11	•	311
	NETHODS					Spain	104 (23.5%)	159 (9.		329
						UK	85 (19.2%)	237 (14	,	243
•	Data were dra	wn from tl	ne Adelphi P	sO Disease Spe	ecific	USA	60 (13.6%)	471 (28		352
	Programme (E	DSP), a cros	Body Mass Index (kg/m ²)							
	retrospective	data collec	n	411	1602		164			
	•			US, France, Gei	Mean (SD)	25.6 (4.4)	26.5 (5	.1)	26.0	
	Spain, and the	•			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	Median (Q1, Q3)	25.1 (4.4)	25.7 (2	3.2, 28.5)	25.
	I <i>i</i>			prized patients	Min, Max	16.1, 48.9	16.6, 69	9.1	15.0	
-	•	•	•	•	•	Current Body Surface Area (BSA%)				
				atter two were	n Maria (CD)	442	1679	F 0)	169	
	•		evere catego	ory (eligible for	systemic	Mean (SD) Median (01-02)	1.4 (2.0) 0 (0, 2.0)	19.7 (1	5.8) 0.0, 25.0)	3.9 2.0
	therapy per la	-			Median (Q1, Q3) Min, Max		•	-		
•	Severity of Ps	O was ther	n retrospecti	vely classified of	,	<i>n, Max</i> 0, 9.0 0, 100.0 0, 7. :ive Location Involvement, n (%)				
	based on eligi	bility for sy	vstemic thera	apy according t	Yes	0	, 1474 (8	37.5%)	105	
	using the mos	st current c	linical marke	ers.	No	442 (100%)	、 210 (12	•	651	
•	_			/stemic therapy	v between	Topical Failure	/		-	
	•		• · ·	ia was assesse	Yes	0	888 (5	52.7%)	125	
					G .	No	361 (81.7%)	415 (2	24.6%)	319
						Missing	81 (18.3%)	381 (2	22.6%)	127
Tab	le 1: Agreement o	on PsO Seve	ritv Between	Clinician and IPC	C Criteria	Takeaway 2: Strat	tification of coh	orts sho	wed no mai	or no
			-	sessment (N=3,866		characteristics. D			•	
		Λ groom out $(0/)$		• •	-	- physician country	Ŭ			
		Agreement (70)	Disagreement (70)	McNemar's p-value	Kappa (95% CI)					
Criteria		84	16	<0.0001	0.68 (0.65-0.70)	- Table 3: Biologic	/ INF Use by Co	norts		
	Sensitive Body Area	66	34	<0.0001	0.35 (0.32-0.38)			A	greement and	l Disag
	Involvementa				х , , , , , , , , , , , , , , , , , , ,		Agreemen	t betwee	en Clinician an	d IPC
	Topical Therapy	48	52	<0.0001	0.02 (-0.01-0.05)	S				
IPC	Failure Meets Any of Above	55	45	<0.0001	0.17 (0.15-0.19)	Jas	Mild		Severe	2
	Criteria		ЧJ	NO.0001	0.17 (0.10-0.19)		*	50/1	EDE /01 0)0/1
Note:	BSA%, Sensitive Body Area are based on m	nost current patient assessme	Biologic/TNF	* 223 (50.5	ן סי נ	525 (31.2	-/0 j			
	sitive body locations included: scalp, neck,	-	-	rs, nails		୍ଟି ତୁତ୍ତି Oral Systemic	cs ^t 168 (38.0)%)	822 (48.8	3%)
Tak	eaway 1 · Prior to	the IDC syste	amic thorany	critoria nublicati	on there was	Š				,

B	ACKGROUN	ID				RESULTS				
•	While many advanced therapies exist for PsO, measures based on extent of skin manifestations (e.g., body surface area (BSA) and Psoriasis Area and Severity Index [PASI]) are used for reimbursement and therapeutic decisions, as systemic therapies are traditionally reserved for patients with				 3,866 PsO patient assessments from Disagreement based on severity was Table 2: Patient Demographics and Current Disagreement Between Clinician Assessme Agree 					
	•		•		Agreement bet	•				
•	moderate-sev		•	Characteristic	Mild	Modera				
	In 2020, the I				N = 442	N=				
	three criteria	(i.e., BSA ≥1	.0%, sensitiv	Age (years)						
	failure of topi	ical therapy	control) tha	n	200	749				
	when estimat	• •	-	Mean (SD)	45.8 (15.3)	42.9 (14.4 ⁻				
		_		Median (Q1,Q3)		•				
	evaluating eli	gionity for s	ystemic the	Min, Max	16.0, 90.0	13.0, 88.0				
						Race, n (%)				
		OBJ	ECTIVES	Caucasian	387 (87.6%)	1472 (87.4				
	To understan	d lovel of ag	roomont ha	Other Races	55 (12.4%)	212 (12.6%				
				Sex, n (%)						
	IPC criteria fo		-	Female	202 (45.7%)	756 (44.9%				
•	Investigate w	hether the l	PC criteria f	or eligibility fo	or systemic	Male	239 (54.1%)	927 (55.0%		
	therapy woul	d identify pa	atients with	Provider & Patient	1 I	•				
	significant dis	sease burde	n or worse c	France	78 (17.6%)	286 (17.0%				
						Germany	19 (4.3%)	342 (20.3%		
						Italy	96 (21.7%)	189 (11.2%		
	NETHODS					Spain	104 (23.5%)	159 (9.4%)		
				ŪK	85 (19.2%)	237 (14.1%				
•	Data were dra	awn from th	e Adelphi P	USA	60 (13.6%)	471 (28.0%				
	Programme (DSP), a cross	s-sectional (with aspects	of	Body Mass Index (kg/m ²)				
	retrospective	data collect	tion) survey	n	411	1602				
	consulting ad			. ,		Mean (SD)	25.6 (4.4)	26.5 (5.1)		
	Spain, and th	•			crinariy, icary,	Median (Q1, Q3)	25.1 (4.4)	25.7 (23.2,		
						Min, Max	16.1, 48.9	16.6, 69.1		
•	Physicians du	U		•	•	Current Body Surface Area (BSA%)				
	mild, modera	te, or severe	e PsO; the la	n	442	1679				
	into a single r	moderate-se	evere catego	Mean (SD)	1.4 (2.0)	19.7 (15.8)				
	therapy per la	abel).		Median (Q1, Q3)	0 (0, 2.0)	15.0 (10.0,				
•	Severity of Ps	•	ratrospactiv	Min, Max	0, 9.0	0, 100.0				
	-		-	Sensitive Location involvement, n (%)						
	based on elig			Yes	0	1474 (87.5				
	using the mo			No	442 (100%)	210 (12.5%				
•	Agreement re	egarding elig	gibility for sy	Topical Failure	_					
	physician asso	essments ar	nd IPC criteri	ia was assesse	ed.	Yes	0	888 (52.7		
						No	361 (81.7%)	415 (24.6		
						Missing	81 (18.3%)	381 (22.6		
Tabl	e 1: Agreement	on PsO Sever	ity Between (Clinician and IF	PC Criteria	Takeaway 2: Stra	tification of coh	orts showe		
			Clinician Ass	essment (N=3,86	56)	characteristics. D	isagreement wa	as most not		
		Agreement (%)	Disagreement (%)	McNemar's p-value	- Kappa (95% CI)	- physician country	y of practice, dr	iven largely		
IPC Criteria		Agreement (70)	bisagreement (70)			Table 2. Dialogic		boute		
	- BSA ≥10%	84	16	<0.0001	0.68 (0.65-0.70)	Table 3: Biologic	C/TNF Use by Co	onorts		
	Sensitive Body Area	66	34	<0.0001	0.35 (0.32-0.38)			Agre		
	Involvement ^a						Agroomon	t hotwoon (
	Topical Therapy	48	52	<0.0001	0.02 (-0.01-0.05)		Agreemen	t between C		
	Failure					Class	Mild			
	Meets Any of Above Criteria	55	45	<0.0001	0.17 (0.15-0.19)					
						Biologic/TNI	* 223 (50.	5%)		
	3SA%, Sensitive Body Area are based on itive body locations included: scalp, nec			, nails		C	ant 4.00 (00	00/)		
						Öral System	cs ^t 168 (38.	0%)		
Tak	away 1 · Prior to	the IDC syste	mic thorany a	ritoria nublicat	tion there was	6				

Takeaway 1: Prior to the IPC systemic therapy criteria publication, there was unmet need regarding patient burden recognition outside of BSA involvement

* Included: ustekinumab, infliximab, etanercept, adalimumab, golimumab ^t Included: methotrexate, cyclosporine, acitretin, apremilast, fumarate


Takeaway 3: Less than half of the patients in the Disagreement Cohort were on biologic therapy, suggesting an opportunity to improve current treatment guidance

	·	pared to 2126 [Agr])	Figure 1: 0 100%				
	Activity for Cohorts N PC Criteria for PsO Se						
		-	90%				
reement and Disagreement Cohorts ician and IPC Disagreement between Clinician and IPC							
ate/Severe	Clinician Mild	Clinician Severe	80%				
= 1684	N= 1702	N= 38					
			70%				
	824	15					
47)	45.9 (14.1)	42.9 (11.2)					
0, 52.0)	45.0 (35.0, 56.0)	42.0 (33.0, 50.0)	60%				
0	17.0, 88.0	27.0, 63.0					
			50%				
.4%)	1490 (87.5%)	35 (92.1%)					
5%)	212 (12.5%)	3 (7.9%)	400/				
			40% —				
9%)	738 (43.4%)	18 (47.4%)					
)%)	960 (56.4%)	20 (52.6%)	30%				
)%)	230 (13.5%)	3 (7.9%)	20%				
3%)	237 (13.9%)	2 (5.3%)	2070				
2%)	311 (18.3%)	4 (10.5%)					
6)	329 (19.3%)	6 (18.4%)	10%				
_%)	243 (14.3%)	14 (36.8%)					
)%)	352 (20.7%)	8 (21.1%)	0%				
	1647	36					
)	26.06 (4.4)	26.9 (7.1)	Agreemer				
2, 28.5)	25.7 (23.1 <i>,</i> 28.1)	24.5 (22.8 <i>,</i> 27.9)					
1	15.6, 64.0	19.0, 51.5	Takeawa				
			red bar)				
	1691	38	(light gre				
8)	3.95 (5.1)	4.0 (2.4)					
0, 25.0)	2.0 (1.0, 5.0)	5.0 (2.0, 6.0)	CO				
	0, 75.0	0, 8.0					
.5%)	1051 (61.8%)	0	P:				
5%)	651 (38.2%)	38 (100%)	d				
			• т				
.7%)	1256 (73.8%)	0					
.6%)	319 (18.7%)	21 (55.3%)	g				
.6%)	127 (7.5%)	17 (44.7%)	O [·]				
ved no maj	or notable difference	s in patient demographic	Se IT				

ed no major notable differences in patient demographic otable with underdiagnosis of PsO severity regardless of y by sensitive location and topical failure criteria

eement and Disagreement Cohorts (N=3,866)

С	Disagreement between Clinician and IPC					
	Clinician Mild	Clinician Severe				
	773 (45.4%)	13 (34.2%)				
	799 (46.9%)	19 (50.0%)				



ent: Mild 🔲 Agreement: Moderate/Severe 📃 Disagreement: Clinician Mild 📕 Disagreement: Clinician Severe

yay 4: PsO patients classified as severe by IPC but mild by clinician (light) experienced notably worse outcomes than the mild agreement cohorts reen bar), including in remission rates and treatment satisfaction

NCLUSION

- sectional study designs.

- PMC6500315.

Alexander Litvintchouk, Jing Zhao, and Oluwakayode Adejoro are employees of Janssen Global Services, LLC, a Johnson & Johnson Company

CO91

Dutcomes of Interest

The level of disagreement prior to publication of IPC criteria for PsO severity was significant among clinicians, with highest discordance found with clinicians estimating lower PsO severity. The snapshot frequencies of biologic/TNF inhibitor use across all groups are low, but may be confounded by the dynamic nature of severity of disease indicating an inherent limitation of cross-

IPC criteria for systemic therapy eligibility may effectively identify patients with significant PsO burden who may otherwise be missed by clinician assessment of BSA alone.

Adoption of the IPC criteria into clinical trials, clinical practice, and reimbursement decisions by payers is considered due to the potential to reduce undertreatment of PsO and therefore improvement of patient outcomes.

REFERENCES AND DISCLOSURES

Strober B, Ryan C, van de Kerkhof P, van der Walt J, Kimball AB, Barker J, Blauvelt A; International Psoriasis Council Board Members an Councilors. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020 Jan;82(1):117-122. doi: 10.1016/j.jaad.2019.08.026. Epub 2019 Aug 16. PMID: 31425723. Strober B, Greenberg JD, Karki C, Mason M, Guo N, Hur P, Zhao Y, Herrera V, Lin F, Lebwohl M. Impact of psoriasis severity on patientreported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. BMJ Open. 2019 Apr 20;9(4):e027535. doi: 10.1136/bmjopen-2018-027535. PMID: 31005939; PMCID:

Thai S, Barlow S, Lucas J, Piercy J, Zhong Y, Zhuo J, Wu JJ. Suboptimal Clinical and Quality of Life Outcomes in Patients with Psoriasis Undertreated with Oral Therapies: International Physician and Patient Survey. Dermatol Ther (Heidelb). 2023 Jun;13(6):1289-1303. do 10.1007/s13555-023-00927-x. Epub 2023 May 31. PMID: 37253874; PMCID: PMC10264339.